REVIEW article
Front. Pharmacol.
Sec. Pharmacology of Infectious Diseases
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1572616
This article is part of the Research TopicTherapeutic and Protective Approaches to Gastrointestinal Tract InfectionsView all 4 articles
Therapeutic and Protective Approaches to Combat Campylobacter jejuni Infections
Provisionally accepted- Division of Microbiology, Department of Biology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Bavaria, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Campylobacter jejuni is a typical zoonotic bacterium, colonizing the gut of many bird species as commensal. In humans, C. jejuni is a major foodborne pathogen. Infection of humans causes campylobacteriosis in the small intestine, constituting a main source of bacteria-dependent gastroenteritis cases worldwide. In particular, the ingestion of under-cooked rooster meat, raw milk and contaminated water, as well as cross-contamination of ready-to-eat food after handling raw chicken meat, are responsible for the majority of C. jejuni infections. As a consequence, infected individuals may acquire watery and/or bloody diarrhea associated with abdominal pain, and eventually post-infection illnesses of the neural system and joints, including the Guillian Barré, Miller Fisher and Reiter syndromes. One therapeutic strategy is to reduce C. jejuni colonization in chicken farms using vaccination, bacteriocins and phage therapy protocols. Prevention approaches during poultry meat processing comprise the compliance to high hygiene standards. Furthermore, substantial progress has been also made in recent years to combat campylobacteriosis using established mouse and in vitro cell model systems. In this regard, specific C. jejuni colonization- and pathogenicity-associated components were considered as favored treatment structures, targeting bacterial movement, host cell interaction, intracellular survival, propagation and spread of the bacteria. This has been complemented by a number of pharmaceutical compounds to reduce C. jejuni-induced epithelial cell damage, inflammation and apoptosis in infected mice. Here we review these novel treatment and prevention as well as “One World - One Health” approaches that aim to diminish the consequences of acute campylobacteriosis and post-infection sequelae in humans.
Keywords: Campylobacter jejuni, Gut Microbiota, epithelial barrier, One Health, phytochemicals, Probiotics, Bacteriophage, Vaccine
Received: 07 Feb 2025; Accepted: 16 Apr 2025.
Copyright: © 2025 Sharafutdinov, Bodo, Tegtmeyer and Backert. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Steffen Backert, Division of Microbiology, Department of Biology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, 91058, Bavaria, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.